Directory
Robert Montal Roura

Robert Montal Roura

Degree: PhD


rmontal.lleida.ics(ELIMINAR)@gencat.cat

Publications

  • Rodríguez, JV; Prieto, A; Vilaprinyo, E; Bonet, M; Diez, M; Salud, A; Montal, R

    Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis (vol 201, 104416, 2024)

    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 202 104466-104466. .

    [doi:10.1016/j.critrevonc.2024.104466]

  • Rodríguez, JV; Prieto, A; Vilaprinyo, E; Bonet, M; Diez, M; Salud, A; Montal, R

    Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis

    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 201 104416-104416. .

    [doi:10.1016/j.critrevonc.2024.104416]

  • O'Rourke, CJ; Salati, M; Rae, C; Carpino, G; Leslie, H; Pea, A; Prete, MG; Bonetti, LR; Amato, F; Montal, R; Upstill-Goddard, R; Nixon, C; Sanchon-Sanchez, P; Kunderfranco, P; Sia, D; Gaudio, E; Overi, D; Cascinu, S; Hogdall, D; Pugh, S; Domingo, E; Primrose, JN; Bridgewater, J; Spallanzani, A; Gelsomino, F; Llovet, JM; Calvisi, DF; Boulter, L; Caputo, F; Lleo, A; Jamieson, NB; Luppi, G; Dominici, M; Andersen, JB; Braconi, C

    Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy

    Gut 73 496-508. .

    [doi:10.1136/gutjnl-2023-330748]

  • Parisi, E; Hidalgo, I; Montal, R; Pallise, O; Tarragona, J; Sorolla, A; Novell, A; Campbell, K; Sorolla, MA; Casali, A; Salud, A

    PLA2G12A as a Novel Biomarker for Colorectal Cancer with Prognostic Relevance

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 24 -. .

    [doi:10.3390/ijms241310889]

  • Ortiz-Barahona, V; Soler, M; Davalos, V; Garcia-Prieto, CA; Janin, M; Setien, F; Fernandez-Rebollo, I; Bech-Serra, JJ; de la Torre, C; Guil, S; Villanueva, A; Zhang, PH; Yang, L; Guarnacci, M; Schumann, U; Preiss, T; Balaseviciute, U; Montal, R; Llovet, JM; Esteller, M

    Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer.

    MOLECULAR CANCER 22 83-83. .

    [doi:10.1186/s12943-023-01785-z]

  • Oronich, A; Pallise, O; Salud, A; Montal, R

    Genomic alterations and targeted therapies in extrahepatic cholangiocarcinoma

    Hepatoma Research 9 -. .

    [doi:10.20517/2394-5079.2023.04]

  • Kudo, M; Montal, R; Finn, RS; Castet, F; Ueshima, K; Nishida, N; Haber, PK; Hu, YY; Chiba, Y; Schwartz, M; Meyer, T; Lencioni, R; Llovet, JM

    Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma treated with Systemic Therapies.

    CLINICAL CANCER RESEARCH 28 3443-3451. .

    [doi:10.1158/1078-0432.CCR-21-3135]

  • Sorolla, MA; Hidalgo, I; Sorolla, A; Montal, R; Pallise, O; Salud, A; Parisi, E

    Microenvironmental Reactive Oxygen Species in Colorectal Cancer: Involved Processes and Therapeutic Opportunities

    Cancers 13 -. .

    [doi:10.3390/cancers13205037]

  • Haber PK; Puigvehí M; Castet F; Lourdusamy V; Montal R; Tabrizian P; Buckstein M; Kim E; Villanueva A; Schwartz M; Llovet JM

    Evidence-based management of Hepatocelluar Carcinoma: Systematic review and meta-analysis of randomized controlled trials (2002-2020).

    Gastroenterology 161 879-898. .

    [doi:10.1053/j.gastro.2021.06.008]

  • Parisi E; Sorolla A; Montal R; González-Resina R; Novell A; Salud A; Sorolla MA

    Prognostic Factors Involved in the Epithelial-Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis.

    Cancers 12 1-28. .

    [doi:10.3390/cancers12113330]

Projects

  • OncoNeoVac, un nuevo enfoque inmunoterapéutico para el tratamiento del melanoma.
  • BIOMARCADORES EN BIOPSIA LÍQUIDA DE COLANGIOCARCINOMA AVANZADO PARA UNA INMUNO-ONCOLOGÍA DE PRECISIÓN
  • Biomarcadores de Respuesta a Inmunoterapia mediante la Inmunofenotipificación Exhaustiva del Adenocarcinoma Gástrico.
  • CONTRATOS JUAN RODÉS
  • AYUDA SEOM - JUAN RODÉS 2021
  • Editing of TERT promoter mutations with CRISPR/Cas9 technology for the treatment of Hepatocellular carcinoma
  • Inmuno-oncología de precisión para el Adenocarcinoma Gástrico.